Genor Biopharma Holdings Ltd. has provided an update on its proposed merger, which involves the issuance of consideration shares under a specific mandate. The company also mentioned a reverse takeover and a new listing application. Additionally, there are plans for a change of company name and an increase in authorized share capital. The proposal includes the adoption of a one-off share option plan. The transaction is contingent upon certain conditions, including the granting of a whitewash waiver. The merger's finalization remains conditional on meeting these prerequisites.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。